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Introduction: Statins may have pleiotropic effects in COPD, but mechanisms remain unclear.
Objectives: To assess the pleiotropic effect of statins in patients with stable COPD on (1): lung function
(2); pulmonary and systemic inﬂammation (3); endothelial function (vascular stiffness) and circulating
vascular growth factors; and (4), serum uric acid levels.
Method: Pilot, double-blind, randomized, placebo-controlled clinical trial in 24 patients with stable
COPD, all statin-naïve, who were randomized (1:1) to receive simvastatin 40 mg/24 h during 12 weeks
(n ¼ 12; 69.0 ± 7.3 years; post-bd FEV1 53.4 ± 10.0% pred.) or placebo (n ¼ 12; 66.4 ± 4.6 years; post-bd
FEV1 48.2 ± 12.6% pred.). Nine patients per group (total n ¼ 18) completed the study.
Results: Lung function, pulmonary and systemic inﬂammatory markers and the degree of vascular
stiffness did not change signiﬁcantly in any group. However, treatment with simvastatin increased the
plasma levels of erythropoietin (Epo) (4.2 ± 2.2 mIU/mL to 6.8 ± 3.2 mlU/mL, p < 0.05) and reduced those
of serum uric acid (7.1 ± 1.3 mg/dL to 6.5 ± 1.4 mg/dL, p < 0.01).
Conclusions: Short-term treatment with simvastatin in stable COPD patients did not modify lung func-
tion, pulmonary and systemic inﬂammation, or vascular stiffness, but it changed Epo and uric acid levels.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by poorly reversible airﬂow limitation associated with pulmonary
and systemic inﬂammation [1e4]. The latter is clinically relevant
since it relates to many of the comorbidities associated with the
disease [3,5e7], and is associated with greater exacerbation rates
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Inc. This is an open access article uStatins inhibit HMC-CoA reductase, lower plasma cholesterol
levels and reduce cardiovascular mortality. Besides, statins can
have anti-inﬂammatory effects [9,10]. These pleiotropic effects have
been demonstrated in animal models [11] but studies in humans
are controversial. On the one hand, several observational trials
suggested that treatment with statins in COPD reduce the fre-
quency andmortality rate from exacerbations and pneumonia, lung
function decline and lung cancer risk [12e17]. On the other, very
recently, Criner et al. published the results of a randomized
controlled trial showing that treatment with simvastatin (40 mg/
day) did not affect exacerbation rates or time to a ﬁrst exacerbation
in COPD patients [18]. Of note, however, COPD patients were
included in this study only if they had not had previous cardio-
vascular events, did not have cardiovascular risk nor were selected
by the level of systemic inﬂammation [18].
The precise biological effects of statins in COPD are also unclearnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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their anti-inﬂammatory effects [20e22], particularly when COPD
coexists with cardiac comorbidity [23], others [19] could not ﬁnd
any effect of statins on several markers of systemic inﬂammation,
including ﬁbrinogen, C-reactive protein [CRP], tumor necrosis fac-
tor-a [TNF-a] and interleukin [IL]-6).
To further explore the pleiotropic effects of statins in COPD, we
designed a randomized pilot clinical trial to investigate compre-
hensively their potential effect on (1): lung function (2); systemic
and pulmonary inﬂammation (3); endothelial function and growth
factors involved in vascular homeostasis (erythropoietin [Epo] and
vascular endothelial growth factor [VEGF]); and (4) serum uric acid
(UA), a biomarker recently associated with the prognosis of COPD
exacerbations [24].
2. Methods
2.1. Study design and ethics
Pilot, double-blind, randomized, placebo-controlled clinical trial
(ClinicalTrial.gov number NCT02070133) performed according to
the Declaration of Helsinki and Good Clinical Practice standards.
The study was approved by the Ethics Committee of the Autono-
mous Community of the Balearic Islands, and all participants signed
the informed consent forms after being fully informed of the na-
ture, goals and design of the study.
Eligible patients (see below) were randomized (1:1) to one of
the following groups: simvastatin 40 mg/24 h or placebo. Study
variables were measured before and after 12 weeks of treatment.
During the study period we monitored possible liver and muscle
disorders (muscle weakness, rhabdomyolisis) caused by treatment
with simvastatin through clinical data per medical history, physical
examination and biomarkers for liver cytolysis and rhabdomyolisis
(AST, ALT, CK).
2.2. Patients
We consecutively evaluated former smokers with stable COPD
and moderate to severe airﬂow limitation [1] from the outpatient
clinic of the Pneumology Department of the Hospital Universitario
Son Dureta/Son Espases. None of them had required hospitalization
or treatment changes within the previous 12 weeks, and had no
other concomitant chronic inﬂammatory disease. Exclusion criteria
also included history of active coronary artery disease, cerebro-
vascular or peripheral vascular disease had a fasting level of total
cholesterol 220 mg/dL and had received statin therapy before.
2.3. Measurements
2.3.1. Lung function
Forced spirometry (GS,Warren E. Collins, Braintree, MA, US) was
performed according to international standards. Spirometric
reference values were those of a Mediterranean population [25].
Arterial blood gases were measured in a blood sample obtained by
radial artery puncture after local anesthesia (IL BG3, Izasa, Spain).
The carbon monoxide diffusion capacity of the lungs (DLCO)
(HypAir Compact þ, Medisoft, Belgium) and the 6 min walking test
were also determined according to international guidelines.
2.3.2. Circulating blood
Between 8 am and 10 am, fasting venous blood samples were
obtained in tubes with EDTA (10 mL) or without EDTA (10 mL) for
biochemical determinations. Immediately after, plasma was sepa-
rated by centrifugation at 200 rpm for 10 min and stored at 80 C.
Total and differential leukocyte count was determinedautomatically in the whole blood sample (Sysmex K-4500, Toa
Medical Electronics Co Ltd, Kobe, Japan). The serum levels of
interleukin (IL) 6 (IL-6), IL-8 concentration and VEGF were deter-
mined by Luminex xMAP (MILLIPLEX MAP High Sensitivity Human
Cytokine Magnetic Bead Panel Merck Millipore, Darmstadt,
German) according to the manufacturer's instructions. The
analytical sensitivity was 0.13e2.000 pg/mL for IL-6 and IL-8, and
3.2e10.000 pg/mL for VEGF. Circulating levels of Epo were deter-
mined by ELISA (eBioscioence, San Diego, USA) with a sensitivity of
100e1.6 mlU/mL. Ultrasensitive C-reactive protein (CRP) levels
were determined by nephelometry.
2.3.3. Sputum
Two sputum specimens from each patient were obtained using
the technique of induced sputum. Patients were pretreated with
400 mcg of salbutamol by inhalation. Pre-induction spirometry
10 min before and 10 min after salbutamol was done. After placing
a nasal clip, induction was started with physiological hypertonic
saline ﬁrst and 3% hypertonic saline then, with an ultrasonic
nebulizer (NE-U17, Omron Healthcare Co., Ltd., Japan). Patients
were asked to expectorate whenever they feel or at every 5 min.
FEV1 was also checked at every 5 min. Sputum samples were kept
in cold place (temp. 4 C) and processed within 2 h. The superna-
tant was frozen at 80 C. The concentration of IL-6 and IL-8 in the
sputum supernatant was determined by Luminex xMAP (MILLI-
PLEX MAP High Sensitivity Human Cytokine Magnetic Bead Panel
Merck Millipore, Darmstadt, German) according to manufacturer's
instructions. The analytical sensitivity of this method was
0.13e2000 pg/mL.
2.3.4. Vascular stiffness
Measurements of vascular stiffness were carried out according
to international recommendations [26]. Brieﬂy, in the morning, in a
roomwith controlled temperature (20-25 C) and the patient lying
supine, we used applanation tonometry (SphygmoCor, AtCor
Medical Pty Ltd, Sydney, Australia) to quantify the speed of the
pulse wave (PWV) and the augmentation index (AI), as previously
reported [27].
2.4. Statistical analysis
Quantitative results are presented as mean ± standard deviation
and categorical variables as absolute number and percentage. All
variables followed a normal distribution (KolmogoroveSmirnov
test). The statistical signiﬁcance of baseline differences between the
simvastatin and placebo groups was analyzed using the Student's t-
test or Chi2 test for unpaired samples. Within each group, differ-
ences observed before and after the intervention were analyzed
with the paired t-test or the McNemar test for paired samples. A p
value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Patient characteristics
Fig. 1 presents the CONSORT ﬂowchart diagram of the study. We
screened 40 patients, of whom 16 did not meet all the inclusion
criteria and had to be excluded. We ﬁnally randomized 24 patients
(12 in each arm). No signiﬁcant differences in age, gender or any
major clinical variables between participants (n ¼ 24) and non-
participants (n ¼ 16) were observed (data not shown).
Of the 24 patients originally randomized, 18 patients (75%)
completed the study, nine in each arm. Two patients (one per arm)
decided to quit the study. One patient in the simvastatin group





9 (75%) completed treatment
2 did not complete tx.
1 had a severe adverse effect
16 patients excluded for not 




9 (75%) completed treatment
2 did not complete tx.
1 died
Fig. 1. CONSORT ﬂowchart diagram of the trial. For further explanations, see text.
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group, one patient died after hospital admission for severe com-
munity acquired pneumonia. Table 1 shows the main demographic,
clinical and functional characteristics at recruitment of the 18 pa-
tients who ﬁnalized the study.3.2. Effects of treatment
After 12 weeks of treatment with simvastatin, a reduction in
total cholesterol (183.6± 29.2mg/dL to 149.2± 23.9mg/dL, p<0.01)
and LDL cholesterol (114.4 ± 25.6 mg/dL to 78.7 ± 18.2 mg/dL,
p<0.01) was observed in the interventional study arm but not in the
control group (total cholesterol from 197.6 ± 27.9 mg/dL to
200.4 ± 27.5 mg/dL and LDL cholesterol from 121.1 ± 18.9 mg/dL to
124.4 ± 20.5 mg/dL). No participants reported adverse effects from
simvastatin treatment.
Table 2 presents the study effects on pulmonary and systemic
inﬂammation, lung function and vascular biology. After 12 weeks ofTable 1
Characteristics of participants at recruitment.
Simvastatin group Placebo group
N 9 9
Age, years 69.3 ± 7.2 66.4 ± 4.6
Male, n (%) 8 (88.9) 7 (77.8)
BMI, kg/m2 30.0 ± 4.7 28.5 ± 6.5
Smoking exposure, pack-years 50.0 ± 33.5 50.4 ± 14.0
GOLD A, n (%) 4 (44.4) 3 (33.3)
GOLD B, n (%) 1 (11.1) 1 (11.1)
GOLD C, n (%) 3 (33.3) 3 (33.3)
GOLD D, n (%) 1 (11.1) 2 (22.2)
Total cholesterol, mg/dL 183.6 ± 29.2 197.6 ± 27.9
Glycemia, mg/dL 106.3 ± 17.9 107.6 ± 18.7
Hemoglobin, g/dL 14.9 ± 1.1 14.2 ± 1.6
Comorbidities
Arterial hypertension, n (%)





LA-b2, n (%) 8 (88.9) 7 (77.8)
LA Anticholinergic, n (%) 7 (77.8) 6 (66.7)
Inhaled corticosteroids, n (%) 6 (66.7) 7 (77.8)
SA-b2, n (%) 4 (44.4) 2 (22.2)













N: number of patients; BMI: body mass index, LA: Long-acting, SA: short-acting,
ASA: acetylsalicylic acid, ACEI: angiotensin converting enzyme inhibitor; ARBs
angiotensin II receptor blocker.simvastatin or placebo treatment, we did not observe any signiﬁ-
cant intragroup differences in markers for pulmonary inﬂamma-
tion (sputum), systemic inﬂammation, or lung function (Table 2),
except for a reduction in the serum levels of UA (from 7.1 ± 1.3 mg/
dL to 6.5 ± 1.4 mg/dL; p<0.01) in the simvastatin-treated group but
not in the placebo group (5.9 ± 2.0 mg/dL to 6.1 ± 1.8 mg/dL)
(Table 2 and Fig. 2, panel A).
Finally, there were no signiﬁcant differences in endothelial
function (vascular stiffness) or VEGF levels (Table 2). Yet, plasma
Epo levels increased signiﬁcantly (4.2 ± 2.2 mlU/ml to 6.8 ± 3.2
mlU/ml, p< 0.05) in the simvastatin-treated but not in the placebo
group (Table 2 and Fig. 2, panel B).
4. Discussion
This pilot randomized placebo-controlled trial failed to
demonstrate a signiﬁcant effect of 12-weeks treatment with sim-
vastatin on most of the variables studied, including lung function,
pulmonary and systemic inﬂammation and vascular stiffness. Yet,
to our knowledge, it is the ﬁrst to show that treatment with sim-
vastatin in patients with stable COPD who were simvastatin-naïve
reduces serum UA levels and increases the plasma Epo levels. The
implications of these ﬁndings deserve further research.
4.1. Previous studies
Several previous observational studies have explored the effects
of treatment with statins in COPD [28e31]. Lahousse L et al. studied
a population of nearly 2700 middle-aged COPD patients who were
followed up to 17 years, and reported that statin treatment was
associated with a 39% decrease in all-cause mortality, and that this
effect was particularly evident (78%) in those individuals withmore
systemic inﬂammation (hsCRP  3 mg/L) [31]. Yet, the precise
mechanisms underlying these effects are unclear, since two previ-
ous randomized clinical trials reported opposite results. Hence,
whereas Lee et al [20] observed a signiﬁcant reduction in some
markers of systemic inﬂammation (IL-6 and CRP), following 6
months of treatment, which appeared to be associated with an
increase in exercise tolerance and a decrease in respiratory symp-
toms, Kaczmarek et al [19] were unable to observe an anti-
inﬂammatory effect of statins (simvastatin) or to show any effect
on lung function (FEV1). Our results are in keeping with this latter
trial [19], since we did not ﬁnd either a signiﬁcant effect of statins
on systemic inﬂammation or lung function. We concur, however,
that the small sample size and short duration of our studymay have
limited our ability to detect a signiﬁcant effect of simvastatin on
these variables. More recently, Criner et al reported negative results
of simvastatin treatment on exacerbation rate and time to ﬁrst
exacerbation in a large, prospective, randomized clinical trial [18].
The short duration of our study did not allowed us to study these
outcomes. Of note however, patients included in Criner's study
represent a very selected subpopulation of COPD patients (i.e.,
those without any previous cardiovascular event and/or need of
statin therapy to reduce their cardiovascular risk) whereas ours
included all comers fulﬁlling the established inclusion criteria of
our study (see above).
4.2. Novel ﬁndings
Our study provides three novel observations. First, we explored
if treatment with simvastatin could have an anti-inﬂammatory
pulmonary effect, an aspect that, to our knowledge, had not been
investigated before. Unfortunately, our results (IL-6 and IL-8
sputum concentrations) were negative, and similar to the lack of
effects observed on systemic inﬂammatory markers (Table 2).
Table 2
Effects of treatment on pulmonary and systemic inﬂammatory markers, lung function, vascular physiology and uric acid.
Simvastatin group Placebo group
Pre Post p Pre Post p
Sputum inﬂammation
IL-6, pg/mL 77.6 ± 92.1 63.4 ± 91.9 0.77 93.8 ± 53.9 154.1 ± 70.5 0.15
IL-8, pg/mL 1069.2 ± 722.8 1304.0 ± 526.8 0.49 1322.2 ± 808.7 1445.5 ± 652.2 0.74
Blood inﬂammation
Leukocytes, 103/mL 7.0 ± 1.9 7.6 ± 1.8 0.15 9.0 ± 2.7 8.3 ± 2.3 0.11
Neutrophils, 103/mL 4.5 ± 1.6 4.9 ± 1.5 0.20 6.0 ± 2.3 5.3 ± 1.9 0.13
IL-6, pg/mL 4.4 ± 2.2 5.6 ± 3.8 0.46 8.3 ± 9.5 7.4 ± 8.5 0.79
IL-8, pg/mL 9.3 ± 3.6 7.4 ± 2.6 0.40 8.4 ± 3.5 8.4 ± 8.2 0.98
CRP, mg/L 3.8 ± 2.0 5.1 ± 5.3 0.51 3.1 ± 2.5 3.8 ± 2.9 0.11
Lung Function
FEV1/FVC, % pred. post-bd. 47.0 ± 9.0 46.3 ± 11.5 0.63 42.0 ± 7.8 41.9 ± 8.2 0.93
FEV1, L post-bd. 1.5 ± 0.4 1.5 ± 0.4 0.55 1.3 ± 0.5 1.3 ± 0.4 0.82
FEV1, % pred. post-bd. 53.4 ± 10.0 53.1 ± 12.9 0.85 48.2 ± 12.6 48.1 ± 10.7 0.97
DLCO, % pred. 60.0 ± 21.1 61.1 ± 22.1 0.77 59.1 ± 12.1 58.6 ± 19.3 0.90
PaO2, mmHg 73.8 ± 5.5 73.5 ± 7.6 0.92 68.7 ± 6.8 70.3 ± 7.6 0.65
6 MWD, m 453.9 ± 58.3 455.6 ± 69.6 0.87 446.3 ± 99.7 444.4 ± 106.0 0.33
Vascular effects
C-AP, mmHg 15.4 ± 3.3 14.3 ± 5.2 0.55 13.1 ± 4.7 16.1 ± 5.3 0.16
AI, % 33.8 ± 6.9 30.5 ± 5.7 0.23 27.5 ± 4.4 30.5 ± 7.5 0.32
PWV, m/s 12.7 ± 4.5 11.8 ± 4.6 0.32 12.2 ± 1.8 13.5 ± 4.3 0.74
Epo, mlU/mL 4.2 ± 2.2 6.8 ± 3.1 0.04 3.8 ± 2.8 3.4 ± 1.6 0.76
VEGF, pg/mL 162.4 ± 59.4 135.5 ± 27.6 0.13 153.8 ± 72.6 174.7 ± 68.6 0.50
Other markers
Uric acid, mg/dL 7.1 ± 1.3 6.5 ± 1.4 0.01 5.9 ± 2.0 6.1 ± 1.8 0.56
FEV1/FVC: forced expiratory volume in the ﬁrst second/forced vital capacity, FEV1: forced expiratory volume in the ﬁrst second; PaO2: partial pressure of arterial oxygen.
6 MWD: 6 min walking distance; C-AP: central pressure, AI: augmentation index, PWV: pulse wave velocity.
Fig. 2. Mean values (±SD) of circulating levels of uric acid and erythropoietin in COPD patients treated with simvastatin (black bars) and in the placebo group (white bars).
Simvastatin reduces (p < 0.01) serum uric acid levels (A), while raising (p < 0.05) the erythropoietin plasma levels (B). No changes were observed in placebo group (A and B).
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prevalent in COPD [32,33], and some studies link systemic
inﬂammation and airﬂow limitation with arterial stiffness, carotid
intima thickness and endothelial dysfunction [34], we also evalu-
ated the potential effects of simvastatin on vascular stiffness and
some vascular growth factors involved in vascular homeostasis.
Results of baseline vascular stiffness in our populationwere similar
to those reported by other authors [27] and did not change after
treatment with simvastatin (Table 2). However, treatment with
simvastatin increased Epo plasma levels by 24.8%. Besides stimu-
lating erythroid precursor cell proliferation and differentiation, Epo
also stimulates the recruitment of circulating endothelial progeni-
tor cells (EPC) and induces angiogenesis [35e37]. Since low circu-
lating EPC levels have been associated with the risk of dying in
patients with cardiovascular disease [38] it is conceivable that
increased serum Epo levels in COPD patients treated with simva-
statin may be one of the mechanisms underlying the beneﬁcial
effects of statins in this disease.And third, some prospective observational studies suggest that
statin therapy is associated with a reduction in hospitalizations due
to COPD exacerbations [28,29]. Recently, Bartziokas K et al. [24]
suggested that increased serum UA levels were associated with
increased mortality and risk of future exacerbations in COPD. Be-
sides, high serum UA levels have been associated with increased
cardiovascular risk and, in patients with cardiovascular disease,
statins have been shown to decrease serum UA levels [39]. Our
results show that treatment with simvastatin in patients with COPD
also reduces serumUA levels (up to 10.1%). It can be speculated that
this may contribute to reduce cardiovascular risk in COPD and,
perhaps, to reduce the severity and/or frequency of exacerbations.4.3. Strengths and limitations
The fact that this is a randomized, double-blind, placebo-
controlled prospective study is a clear strength of our study. We
acknowledge, however, that due to its pilot nature, the reduced
C. Balaguer et al. / Contemporary Clinical Trials Communications 2 (2016) 91e96 95number of patients completing the study and its short duration are
clear limitations. In fact, the reduced number of patients can be
responsible for a type I error whereas the lack of a treatment effect
on some of the variables studied might be due to a lack of statistical
power. However, our results provide novel interesting observations
that we think deserve further exploration in larger and longer co-
horts of COPD patients that somehow can be done as a response to
the study of Criner GJ et al. widening the proﬁle of COPD patients
included in it [18].
5. Conclusions
The results of this pilot randomized clinical trial do not support
any signiﬁcant effect of simvastatin treatment in patients with
stable COPD on pulmonary and systemic inﬂammation, lung func-
tion and/or vascular biology. Yet, we found that it signiﬁcantly in-
creases Epo plasma levels and reduces serum UA levels. The
potential clinical implications of these ﬁndings deserve further
research.
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